Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163295 | 0.86 | TP53 (0.83) | TP53MEN1KMT2ASMN1; SMN2LTB4R2 | |
| SCHEMBL14229445 | 0.86 | TP53 (0.62) | TP53MEN1KMT2ASMN1; SMN2LTB4R2 | |
| SCHEMBL14174738 | 0.85 | TP53 (0.65) | TP53MEN1KMT2ASMN1; SMN2LTB4R2 | |
| SCHEMBL4154740 | 0.83 | TP53 (0.58) | TP53MEN1KMT2ASMN1; SMN2LTB4R2 | |
| SCHEMBL14174764 | 0.78 | TP53 (0.51) | TP53MEN1KMT2ASMN1; SMN2LTB4R2 | |
| SCHEMBL4164723 | 0.77 | TP53 (0.78) | TP53MEN1KMT2ASMN1; SMN2LTB4R2 | |
| SCHEMBL14174765 | 0.77 | TP53 (0.50) | TP53MEN1KMT2ASMN1; SMN2LTB4R2 | |
| SCHEMBL4153434 | 0.77 | TP53 (0.68) | TP53SMN1; SMN2LTB4R2NPC1JAK2 | |
| SCHEMBL4173721 | 0.76 | MLYCD (0.48) | — | |
| SCHEMBL4168719 | 0.76 | OPRM1 (0.48) | TP53SMN1; SMN2CNR2OPRM1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | TP53 1939/4885MEN1 4879/4885KMT2A 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.